Request To Submit a Two-Part Application-Northwest Medical Isotopes, LLC, 63501-63504 [2013-24882]
Download as PDF
Federal Register / Vol. 78, No. 206 / Thursday, October 24, 2013 / Notices
in confidence by indemnity applicants,
and material that is likely to disclose
trade secrets or other privileged or
confidential information, and because it
is important to keep the values of
objects to be indemnified, and the
methods of transportation and security
measures confidential, I have
determined that that the meeting will be
closed to the public pursuant to section
552b(c)(4) of Title 5 U.S.C., as amended.
I have made this determination under
the authority granted me by the
Chairman’s Delegation of Authority to
Close Advisory Committee Meetings,
dated July l9, l993.
Dated: October 21, 2013.
Lisette Voyatzis,
Committee Management Officer.
[FR Doc. 2013–25074 Filed 10–23–13; 8:45 am]
BILLING CODE 7536–01–P
NATIONAL FOUNDATION ON THE
ARTS AND THE HUMANITIES
Meetings of Humanities Panel
National Endowment for the
Humanities.
ACTION: Notice of meetings.
AGENCY:
Pursuant to section 10(a)(2) of
the Federal Advisory Committee Act (5
U.S.C. App.), notice is hereby given that
eleven meetings of the Humanities
Panel will be held during November,
2013 as follows. The purpose of the
meetings is for panel review, discussion,
evaluation, and recommendation of
applications for financial assistance
under the National Foundation on the
Arts and Humanities Act of 1965 (20
U.S.C. 951–960, as amended).
DATES: See SUPPLEMENTARY INFORMATION
section for meeting dates.
ADDRESSES: The meetings will be held at
the Old Post Office Building, 1100
Pennsylvania Ave. NW., Washington,
DC 20506. See SUPPLEMENTARY
INFORMATION section for meeting room
numbers.
FOR FURTHER INFORMATION CONTACT:
Lisette Voyatzis, Committee
Management Officer, 1100 Pennsylvania
Ave. NW., Room 529, Washington, DC
20506, or call (202) 606–8322. Hearingimpaired individuals are advised that
information on this matter may be
obtained by contacting the National
Endowment for the Humanities’ TDD
terminal at (202) 606–8282.
SUPPLEMENTARY INFORMATION:
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
Meetings
1. Date: November 1, 2013.
Time: 8:30 a.m. to 5:00 p.m.
Room: 415.
VerDate Mar<15>2010
17:25 Oct 23, 2013
Jkt 232001
This meeting will discuss
applications on the subjects of the
History of Science, Technology, and
Medicine for the Humanities Collections
and Reference Resources grant program,
submitted to the Division of
Preservation and Access.
2. Date: November 1, 2013.
Time: 8:30 a.m. to 5:00 p.m.
Room: 421.
This meeting will discuss
applications on the subject of Art
History for the America’s Historical and
Cultural Organizations: Implementation
Grants, submitted to the Division of
Public Programs.
3. Date: November 4, 2013.
Time: 8:30 a.m. to 5:00 p.m.
Room: 421.
This meeting will discuss
applications on the subjects of World
History and Culture for the America’s
Historical and Cultural Organizations:
Implementation Grants, submitted to the
Division of Public Programs.
4. Date: November 5, 2013.
Time: 8:30 a.m. to 5:00 p.m.
Room: 421.
This meeting will discuss
applications on the subject of U.S.
History for the America’s Media Makers:
Production Grants, submitted to the
Division of Public Programs.
5. Date: November 5, 2013.
Time: 8:30 a.m. to 5:00 p.m.
Room: 415.
This meeting will discuss
applications on the subjects of U.S.
History and Culture for the Humanities
Collections and Reference Resources
grant program, submitted to the Division
of Preservation and Access.
6. Date: November 7, 2013.
Time: 8:30 a.m. to 5:00 p.m.
Room: 415.
This meeting will discuss
applications on the subjects of U.S.
History and Culture for the Humanities
Collections and Reference Resources
grant program, submitted to the Division
of Preservation and Access.
7. Date: November 7, 2013.
Time: 8:30 a.m. to 5:00 p.m.
Room: 421.
This meeting will discuss
applications on the subject of American
Studies for America’s Historical and
Cultural Organizations: Implementation
Grants, submitted to the Division of
Public Programs.
8. Date: November 19, 2013.
Time: 8:30 a.m. to 5:00 p.m.
Room: 421.
This meeting will discuss
applications on the subject of U.S.
History for America’s Historical and
Cultural Organizations: Implementation
Grants, submitted to the Division of
Public Programs.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
63501
9. Date: November 19, 2013.
Time: 8:30 a.m. to 5:00 p.m.
Room: 415.
This meeting will discuss
applications on the subject of American
Studies for the Humanities Collections
and Reference Resources grant program,
submitted to the Division of
Preservation and Access.
10. Date: November 22, 2013.
Time: 8:30 a.m. to 5:00 p.m.
Room: 415.
This meeting will discuss
applications on the subject of World
Studies for the Humanities Collections
and Reference Resources grant program,
submitted to the Division of
Preservation and Access.
11. Date: November 30, 2013.
Time: 8:30 a.m. to 5:00 p.m.
Room: 415.
This meeting will discuss
applications on the subjects of New
World Archaeology and Culture for the
Humanities Collections and Reference
Resources grant program, submitted to
the Division of Preservation and Access.
Because these meetings will include
review of personal and/or proprietary
financial and commercial information
given in confidence to the agency by
grant applicants, the meetings will be
closed to the public pursuant to sections
552b(c)(4) and 552b(c)(6) of Title 5
U.S.C., as amended. I have made this
determination pursuant to the authority
granted me by the Chairman’s
Delegation of Authority to Close
Advisory Committee Meetings dated
July 19, 1993.
Dated: October 21, 2013.
Lisette Voyatzis,
Committee Management Officer.
[FR Doc. 2013–25080 Filed 10–23–13; 8:45 am]
BILLING CODE 7536–01–P
NUCLEAR REGULATORY
COMMISSION
[Project No. 0803; NRC–2013–0235]
Request To Submit a Two-Part
Application—Northwest Medical
Isotopes, LLC
Nuclear Regulatory
Commission.
ACTION: Exemption.
AGENCY:
The U.S. Nuclear Regulatory
Commission (NRC) is issuing an
exemption in response to an August 9,
2013, letter from Northwest Medical
Isotopes, LLC (NWMI). In this letter,
NWMI requested an exemption from
certain regulatory requirements, which,
if granted, would allow the submittal of
a construction permit application for a
SUMMARY:
E:\FR\FM\24OCN1.SGM
24OCN1
63502
Federal Register / Vol. 78, No. 206 / Thursday, October 24, 2013 / Notices
medical radioisotope production facility
in two parts. The NRC staff has
reviewed this request and determined
that it is appropriate to grant the
exemption, as requested.
ADDRESSES: Please refer to Docket ID
NRC–2013–0235 when contacting the
NRC about the availability of
information regarding this document.
You may access publicly-available
information related to this action by the
following methods:
• Federal Rulemaking Web site: Go to
https://www.regulations.gov and search
for Docket ID NRC–2013–0235. Address
questions about NRC dockets to Carol
Gallagher; telephone: 301–287–3422;
email: Carol.Gallagher@nrc.gov. For
technical questions, contact the
individual(s) listed in the FOR FURTHER
INFORMATION CONTACT section of this
document.
• NRC’s Agencywide Documents
Access and Management System
(ADAMS): You may access publicly
available documents online in the NRC
Library at https://www.nrc.gov/readingrm/adams.html. To begin the search,
select ‘‘ADAMS Public Documents’’ and
then select ‘‘Begin Web-based ADAMS
Search.’’ For problems with ADAMS,
please contact the NRC’s Public
Document Room (PDR) reference staff at
1–800–397–4209, 301–415–4737, or by
email to pdr.resource@nrc.gov. The
ADAMS accession number for each
document referenced in this document
(if that document is available in
ADAMS) is provided the first time that
the document is referenced.
• NRC’s PDR: You may examine and
purchase copies of public documents at
the NRC’s PDR, Room O1–F21, One
White Flint North, 11555 Rockville
Pike, Rockville, Maryland 20852.
FOR FURTHER INFORMATION CONTACT:
Steven Lynch, Office of Nuclear Reactor
Regulation, U.S. Nuclear Regulatory
Commission, Washington, DC 20555–
0001; telephone: 301–415–1524; email:
Steven.Lynch@nrc.gov.
SUPPLEMENTARY INFORMATION: The
following sections include the text of
the exemption in its entirety as it will
be issued to NWMI.
mstockstill on DSK4VPTVN1PROD with NOTICES
1.0
Background
Currently, the United States receives
all of its supply of molybdenum-99 (Mo99) from international sources. In recent
years, outages at these international
facilities have disrupted global supply
and created a need to establish domestic
Mo-99 production within the United
States. In response to this need, NWMI
stated in a letter dated August 9, 2013
(ADAMS Accession No. ML13227A295),
that it intends to ‘‘design and construct
VerDate Mar<15>2010
17:25 Oct 23, 2013
Jkt 232001
a [radioisotope production facility] and
intends to produce Mo-99’’ in order to
meet the emerging domestic demands
for Mo-99 and its decay product,
technetium-99m, in nuclear medicine
procedures. Northwest Medical
Isotopes, LLC, has proposed to submit
an application to construct a
radioisotope production facility
pursuant to the requirements of part 50
of Title 10 of the Code of Federal
Regulations (10 CFR), ‘‘Domestic
Licensing of Production and Utilization
Facilities,’’ and in accordance with 10
CFR 2.101(a)(5) for the purpose of
producing Mo-99. As an applicant for a
permit to construct such a facility,
NWMI will be subject to all applicable
rules, regulations, and orders of the NRC
now or hereafter in effect.
Generally speaking, production and
utilization facility applicants subject to
10 CFR 51.20(b) 1 may submit the
information required for a construction
permit, under 10 CFR part 50, in two
parts, in accordance with the provisions
of 10 CFR 2.101(a)(5). These provisions
state that one part of the submittal must
include the environmental report
required by 10 CFR 50.30(f), while the
other part must include the preliminary
safety analysis report required by 10
CFR 50.34(a). Either part of the
construction permit application may be
submitted first as long as the submission
of each part of the application does not
precede or follow the other by longer
than six months. However, the first part
submitted must also contain the
following:
• The description and safety
assessment of the site required by 10
CFR 50.34(a)(1),
• the filing fee required by 10 CFR
50.30(e) and 10 CFR 170.21,
• the general information required by
10 CFR 50.33, and
• the agreement limiting access to
Classified Information required by 10
CFR 50.37.
Thus, 10 CFR 2.101(a)(5) provides
that applicable preliminary safety
analysis report information required by
10 CFR 50.34(a)(2)–(a)(13) need not
accompany the first part of the
submittal. In order to facilitate the
review of its application, NWMI would
like to submit its application in two
parts, as described above; however,
based on the current language of 10 CFR
51.20, it cannot do so unless granted an
exemption from certain provisions of 10
CFR 2.101(a)(5) by the Commission.
The NRC staff previously addressed
an exemption request from SHINE
1 10 CFR 51.20(b) enumerates the types of
licensing and regulatory actions requiring an
environmental impact statement or a supplement to
an environmental impact statement.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Medical Technologies, Inc. (SHINE) to
submit is construction permit
application in two parts. The NRC staff
responded to a letter from SHINE, dated
July 10, 2012 (ADAMS Accession No.
ML12214A434), that asked whether
production or utilization facility
applicants could submit a construction
permit application in two parts even if
an environmental impact statement is
not explicitly required for the
application by 10 CFR 51.20(b).
In a letter dated December 7, 2012
(ADAMS Accession No. ML12319A192),
the NRC staff responded:
SHINE’s proposed action for licensing a
medical isotope production facility is not an
action identified in 51.20(b); therefore, 10
CFR 2.101(a)(5) is not applicable to SHINE’s
licensing proposal. However, SHINE could
apply for an exemption under 10 CFR 50.12
in order to submit its application for a
construction permit in two parts as described
in 10 CFR 2.101(a)(5).
The NRC staff also explained that
should an exemption to 10 CFR
2.101(a)(5) be sought, the request must
set forth existing special circumstances
warranting the exemption, as well as
provide the proposed contents of each
part of the construction permit
application.
Similarly, NWMI has proposed to
submit an application requesting the
issuance of a construction permit for a
medical radioisotope production
facility—a licensing action not
identified in 10 CFR 51.20(b). Therefore,
its application for a construction permit
cannot be submitted in two parts under
10 CFR 2.101(a)(5) unless an exemption
is granted by the Commission.
2.0 Request/Action
Section 2.101(a)(5) of 10 CFR states,
in part:
An applicant for a construction permit
under part 50 of this chapter . . . for a
production or utilization facility which is
subject to § 51.20(b) of this chapter, and is of
the type specified in § 50.21(b)(2) or (b)(3) or
§ 50.22 of this chapter . . . may submit the
information required of applicants by part 50
. . . of this chapter in two parts.
By its letter dated August 9, 2013,
NWMI requests an exemption from the
provision of 10 CFR 2.101(a)(5) that
applications for a construction permit
under 10 CFR part 50 must be of the
type requiring an environmental impact
statement or a supplement to an
environmental impact statement as
described in 10 CFR 51.20(b). The
exemption would allow NWMI to
submit a portion of its construction
permit up to six months prior to the
submittal of the remainder of the
application regardless of whether an
environmental impact statement or a
E:\FR\FM\24OCN1.SGM
24OCN1
Federal Register / Vol. 78, No. 206 / Thursday, October 24, 2013 / Notices
supplement to an environmental impact
statement is prepared for its
construction permit application.
Specifically, in accordance with the
provisions of 10 CFR 2.101(a)(5), NWMI
proposes to submit the following in part
one of its construction permit
application:
• The description and safety
assessment of the site required by 10
CFR 50.34(a)(1),
• the environmental report required
by 10 CFR 50.30(f),
• the filing fee required by 10 CFR
50.30(e) and 10 CFR 170.21,
• the general information required by
10 CFR 50.33, and
• the agreement limiting access to
Classified Information required by 10
CFR 50.37.
Part two of NWMI’s construction
permit application will contain the
remainder of the preliminary safety
analysis report required by 10 CFR
50.34(a) and 2.101(a)(5). Northwest
Medical Isotopes, LLC, has proposed to
‘‘design and construct a [radioisotope
production facility] and intends to
produce Mo–99.’’ In its request for an
exemption from certain requirements of
10 CFR 2.101(a)(5), NWMI states that
the ‘‘demand for medical isotopes is a
significant national public health and
safety concern,’’ and the ability to
submit its construction permit
application in two parts would ‘‘allow
for an earlier determination as to
whether an [environmental impact
statement] is required, allowing a
potential earlier completion of the
environmental review and ultimate
issuance of the Construction Permit
. . .’’
mstockstill on DSK4VPTVN1PROD with NOTICES
3.0
Discussion
To docket NWMI’s construction
permit application in two parts under
10 CFR 2.101(a)(5), as proposed, an
exemption to the regulations is required.
Pursuant to 10 CFR 50.12, the
Commission may, upon application by
any interested person or upon its own
initiative, grant exemptions from the
requirements of 10 CFR part 50 when (1)
the exemptions are authorized by law,
will not present an undue risk to public
health or safety, and are consistent with
the common defense and security; and
(2) when special circumstances are
present. While the action requested is
not for an exemption to a 10 CFR part
50 regulation, it is appropriate to
evaluate this exemption request using
the criteria of 10 CFR 50.12 because an
application for a construction permit for
a radioisotope production facility
cannot be accepted for docketing in
accordance with 10 CFR 2.101(a) unless
VerDate Mar<15>2010
17:25 Oct 23, 2013
Jkt 232001
it meets the requirements of 10 CFR part
50.
Special Circumstances
The application of 10 CFR 2.101(a)(5)
is limited to applications for licensing
actions that meet the criteria for
environmental impact statements as
described in the provisions of 10 CFR
51.20(b) and to facilities of the types
specified in 10 CFR 50.21(b)(2) or (b)(3)
or 10 CFR 50.22. Northwest Medical
Isotopes, LLC, has proposed to submit
an application requesting the issuance
of a construction permit for a medical
radioisotope production facility—a
licensing action not identified in 10 CFR
51.20(b). Consequently, its application
for a construction permit cannot be
submitted in two parts under 10 CFR
2.101(a)(5) unless an exemption is
granted by the Commission. The
Commission will not consider granting
an exemption under 10 CFR 50.12
unless special circumstances are
present. One of the special
circumstances listed in 10 CFR
50.12(a)(2) is ‘‘(ii) [a]pplication of the
regulation in the particular
circumstances would not serve the
underlying purpose of the rule or is not
necessary to achieve the underlying
purpose of the rule.’’ Therefore, should
the Commission determine that the
underlying purpose of 10 CFR
2.101(a)(5) is achieved, application of
the regulation would not be necessary,
and the special circumstances would
exist for granting of an exemption from
certain requirements of 10 CFR
2.101(a)(5).
The underlying purpose of the 10 CFR
2.101(a)(5) provision that allows certain
applicants to submit an application for
a construction permit in two parts is to
enable the NRC review of significant
portions of the application, as they
become available, without unnecessary
delay. The provision for two-part
construction permit application
submittals was added as an amendment
to the regulations of 10 CFR part 2,
‘‘Agency Rules of Practice and
Procedure,’’ on April 24, 1974 (39 FR
14506). The intent of this final rule was
to ‘‘reduce the time required to bring on
line nuclear power plants which satisfy
all environmental and safety
requirements . . . [and remove]
unnecessary obstacles to the
construction of power plants needed to
meet the nation’s energy needs.’’
Recognizing the procedural nature of
the amendment, the Commission made
the language of the final rule effective
without the customary 30-day notice. It
is consistent with the procedural nature
of and rationale for the rule to allow
NWMI to submit its construction permit
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
63503
application in two parts to facilitate the
licensing process of this facility and
NWMI’s effort to respond to the nation’s
demand for a domestic supply of Mo-99.
Furthermore, when the rule was
originally written, there was a ‘‘deep
national concern over energy sources
and supply.’’ Similarly, there currently
exists a national concern over the
sources and supply of Mo-99 in the
United States. Recognizing this concern,
the U.S. Department of Energy (DOE)
and the National Nuclear Security
Administration (NNSA) are supporting
four separate entities in the
development of low enriched uranium
technologies to accelerate commercial
production of Mo-99 in the United
States through the Global Threat
Reduction Initiative.2 By producing Mo99 to meet emerging domestic needs,
NWMI’s proposed medical radioisotope
production facility supports the efforts
of DOE and NNSA and is in alignment
with the underlying purpose of 10 CFR
2.101(a)(5). Therefore, since the
underlying purpose of the rule is
achieved, application of the regulation
is not necessary, and the special
circumstances, required by 10 CFR
50.12(a)(2)(ii), exist for granting an
exemption from certain requirements of
10 CFR 2.101(a)(5).
Additionally, in 2007, the rule
language was modified to include
applicants seeking combined licenses
under 10 CFR part 52, ‘‘Licenses,
Certifications, and Approvals for
Nuclear Power Plants’’ (72 FR 49412).
The Commission determined that
‘‘[t]here are no considerations unique to
combined licenses which would weigh
against allowing a combined license
applicant to submit a two part
application under paragraph (a)(5) of
§ 2.101.’’ Similarly, the NRC staff
concludes that given the procedural
nature of this rule, there are no unique
considerations for medical radioisotope
production facilities that would weigh
against allowing an applicant such as
NWMI to submit a two-part application
under 10 CFR 2.101(a)(5).
Authorized by Law
This exemption would allow NWMI
to submit its application for a 10 CFR
part 50 construction permit in two parts,
as provided for in 10 CFR 2.101(a)(5).
The exemption would not change the
quality or content of the environmental
report or the preliminary safety analysis
report. The NRC staff has determined
that special circumstances exist to
2 To learn more about the Global Threat
Reduction Initiative and U.S. Department of
Energy’s support of domestic Mo-99 production,
please visit https://nnsa.energy.gov/.
E:\FR\FM\24OCN1.SGM
24OCN1
63504
Federal Register / Vol. 78, No. 206 / Thursday, October 24, 2013 / Notices
support the issuance of an exemption.
Thus, the granting of the proposed
exemption is consistent with the Atomic
Energy Act of 1954, as amended, and
the Commission’s regulations.
Therefore, the exemption is authorized
by law.
No Undue Risk to Public Health and
Safety
As described above, the requested
exemption is procedural in nature and
does not alter any substantive safety
requirements regarding the content of a
construction permit application. Due to
the procedural nature of this request, no
new accident precursors are created by
allowing an applicant to submit a
construction permit application in two
parts; thus, the probability of postulated
accidents is not increased. Similarly, the
consequences of postulated accidents
are not increased by an exemption that
authorizes an application to be
submitted in two parts. Therefore, there
is no undue risk 3 to public health and
safety.
mstockstill on DSK4VPTVN1PROD with NOTICES
Consistent With Common Defense and
Security
As discussed above, the proposed
exemption would allow NWMI to
submit its application for a 10 CFR part
50 construction permit application in
two parts as provided for in 10 CFR
2.101(a)(5). The timing of submitting a
construction permit application has no
relation to security issues. Therefore,
the common defense and security is not
impacted by this exemption.
4.0 Conclusion
Accordingly, the Commission has
determined that, pursuant to 10 CFR
50.12, the exemption is authorized by
law, will not present an undue risk to
the public health and safety, and is
consistent with the common defense
and security. Also, special
circumstances are present. Therefore,
pursuant to 10 CFR 50.12, the
Commission hereby grants NWMI an
exemption from the 10 CFR 2.101(a)(5)
requirement that limits the regulation’s
applicability to licensing and regulatory
actions requiring environmental impact
statements, as described in the
provisions of 10 CFR 51.20(b). The
exemption granted allows NWMI to
submit the construction permit
application for its medical radioisotope
production facility in two parts, in
accordance with the remainder of the
provisions of 10 CFR 2.101(a)(5).
Pursuant to 10 CFR 51.32, the
Commission has determined that the
granting of this exemption will not have
a significant effect on the quality of the
human environment as it is procedural
in nature. Furthermore, the Commission
has determined that this exemption
request meets the criteria in 10 CFR
51.22(c)(25) for a licensing action that is
categorically excluded from the
requirement to prepare an
environmental assessment because the
granting of this exemption: (1) Does not
involve a significant increase in the
probability or consequences of an
accident previously evaluated, does not
create the possibility of a new or
different kind of accident from that
previously evaluated, and does not
involve a significant reduction in the
margin of safety and, thus there is no
significant hazards consideration; (2)
does not authorize the release of
effluents, thus there is no significant
change in the types or significant
increase in the amounts of any effluents
that may be released offsite; (3) neither
authorizes new radiological hazards nor
increases existing radiological hazards,
thus there is no significant increase in
individual or cumulative public or
occupational radiation exposure; (4)
does not authorize construction, thus
there is no significant construction
impact; (5) does not authorize any
placement of radiological components at
a facility or create any new accident
precursors, thus there is no significant
increase in the potential for or
consequences from radiological
accidents; and (6) allows the submission
of a construction permit application in
two parts, and thus involves a
scheduling requirement in accordance
with 10 CFR 51.22(c)(25)(vi)(G). This
exemption is effective upon issuance to
NWMI.
Dated at Rockville, Maryland, this 7th day
of October, 2013.
For the Nuclear Regulatory Commission.
Lawrence E. Kokajko,
Director, Division of Policy and Rulemaking,
Office of Nuclear Reactor Regulation.
[FR Doc. 2013–24882 Filed 10–23–13; 8:45 am]
BILLING CODE 7590–01–P
3 Risk is defined as the probability of an accident
multiplied by the consequences of an accident.
More information on risk as it is applies to NRC
regulatory activities can be found in the
Commission White Paper on Risk-Informed and
Performance Based Regulation, SECY–98–144
(ADAMS Accession No. ML003753601).
VerDate Mar<15>2010
17:25 Oct 23, 2013
Jkt 232001
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
NUCLEAR REGULATORY
COMMISSION
[Docket Nos. 52–027 and 52–028; NRC–
2008–0441]
Virgil C. Summer Nuclear Station,
Units 2 and 3; South Carolina Electric
and Gas; Changes to the Primary
Sampling System
Nuclear Regulatory
Commission.
ACTION: Exemption and combined
license amendment; issuance.
AGENCY:
The U.S. Nuclear Regulatory
Commission (NRC) is granting an
exemption to allow a departure from the
certification information of Tier 1 of the
generic design control document (DCD)
and issuing License Amendment No. 8
to Combined Licenses (COL), NPF–93
and NPF–94. The COLs were issued to
South Carolina Electric and Gas
(SCE&G) and South Carolina Public
Service Authority (Santee Cooper) (the
licensee), for construction and operation
of the Virgil C. Summer Nuclear Station
(VCSNS), Units 2 and 3 located in
Fairfield County, South Carolina. The
amendment requests to modify the
Primary Sampling System (PSS) design,
including changes to Tier 1 information
located in Tables 2.2.1–2, 2.3.13–1, and
2.3.13–3, Figures 2.2.1–1 ‘‘Containment
System’’ and 2.3.13–1 ‘‘Primary
Sampling System,’’ and Subsection
2.3.13, ‘‘Primary Sampling System’’ of
the Updated Final Safety Analysis
Report (UFSAR). The granting of the
exemption allows the changes to Tier 1
information asked for in the
amendment. Because the acceptability
of the exemption was determined in
part by the acceptability of the
amendment, the exemption and
amendment are being issued
concurrently.
SUMMARY:
Please refer to Docket ID
NRC–2008–0441 when contacting the
NRC about the availability of
information regarding this document.
You may access publicly-available
information related to this action by the
following methods:
• Federal Rulemaking Web site: Go to
https://www.regulations.gov and search
for Docket ID NRC–2008–0441. Address
questions about NRC dockets to Carol
Gallagher; telephone: 301–287–3422;
email: Carol.Gallagher@nrc.gov. For
technical questions, contact the
individual listed in the FOR FURTHER
INFORMATION CONTACT section of this
document.
• NRC’s Agencywide Documents
Access and Management System
(ADAMS): You may access publicly
ADDRESSES:
E:\FR\FM\24OCN1.SGM
24OCN1
Agencies
[Federal Register Volume 78, Number 206 (Thursday, October 24, 2013)]
[Notices]
[Pages 63501-63504]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-24882]
=======================================================================
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
[Project No. 0803; NRC-2013-0235]
Request To Submit a Two-Part Application--Northwest Medical
Isotopes, LLC
AGENCY: Nuclear Regulatory Commission.
ACTION: Exemption.
-----------------------------------------------------------------------
SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) is issuing an
exemption in response to an August 9, 2013, letter from Northwest
Medical Isotopes, LLC (NWMI). In this letter, NWMI requested an
exemption from certain regulatory requirements, which, if granted,
would allow the submittal of a construction permit application for a
[[Page 63502]]
medical radioisotope production facility in two parts. The NRC staff
has reviewed this request and determined that it is appropriate to
grant the exemption, as requested.
ADDRESSES: Please refer to Docket ID NRC-2013-0235 when contacting the
NRC about the availability of information regarding this document. You
may access publicly-available information related to this action by the
following methods:
Federal Rulemaking Web site: Go to https://www.regulations.gov and search for Docket ID NRC-2013-0235. Address
questions about NRC dockets to Carol Gallagher; telephone: 301-287-
3422; email: Carol.Gallagher@nrc.gov. For technical questions, contact
the individual(s) listed in the FOR FURTHER INFORMATION CONTACT section
of this document.
NRC's Agencywide Documents Access and Management System
(ADAMS): You may access publicly available documents online in the NRC
Library at https://www.nrc.gov/reading-rm/adams.html. To begin the
search, select ``ADAMS Public Documents'' and then select ``Begin Web-
based ADAMS Search.'' For problems with ADAMS, please contact the NRC's
Public Document Room (PDR) reference staff at 1-800-397-4209, 301-415-
4737, or by email to pdr.resource@nrc.gov. The ADAMS accession number
for each document referenced in this document (if that document is
available in ADAMS) is provided the first time that the document is
referenced.
NRC's PDR: You may examine and purchase copies of public
documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555
Rockville Pike, Rockville, Maryland 20852.
FOR FURTHER INFORMATION CONTACT: Steven Lynch, Office of Nuclear
Reactor Regulation, U.S. Nuclear Regulatory Commission, Washington, DC
20555-0001; telephone: 301-415-1524; email: Steven.Lynch@nrc.gov.
SUPPLEMENTARY INFORMATION: The following sections include the text of
the exemption in its entirety as it will be issued to NWMI.
1.0 Background
Currently, the United States receives all of its supply of
molybdenum-99 (Mo-99) from international sources. In recent years,
outages at these international facilities have disrupted global supply
and created a need to establish domestic Mo-99 production within the
United States. In response to this need, NWMI stated in a letter dated
August 9, 2013 (ADAMS Accession No. ML13227A295), that it intends to
``design and construct a [radioisotope production facility] and intends
to produce Mo-99'' in order to meet the emerging domestic demands for
Mo-99 and its decay product, technetium-99m, in nuclear medicine
procedures. Northwest Medical Isotopes, LLC, has proposed to submit an
application to construct a radioisotope production facility pursuant to
the requirements of part 50 of Title 10 of the Code of Federal
Regulations (10 CFR), ``Domestic Licensing of Production and
Utilization Facilities,'' and in accordance with 10 CFR 2.101(a)(5) for
the purpose of producing Mo-99. As an applicant for a permit to
construct such a facility, NWMI will be subject to all applicable
rules, regulations, and orders of the NRC now or hereafter in effect.
Generally speaking, production and utilization facility applicants
subject to 10 CFR 51.20(b) \1\ may submit the information required for
a construction permit, under 10 CFR part 50, in two parts, in
accordance with the provisions of 10 CFR 2.101(a)(5). These provisions
state that one part of the submittal must include the environmental
report required by 10 CFR 50.30(f), while the other part must include
the preliminary safety analysis report required by 10 CFR 50.34(a).
Either part of the construction permit application may be submitted
first as long as the submission of each part of the application does
not precede or follow the other by longer than six months. However, the
first part submitted must also contain the following:
---------------------------------------------------------------------------
\1\ 10 CFR 51.20(b) enumerates the types of licensing and
regulatory actions requiring an environmental impact statement or a
supplement to an environmental impact statement.
---------------------------------------------------------------------------
The description and safety assessment of the site required
by 10 CFR 50.34(a)(1),
the filing fee required by 10 CFR 50.30(e) and 10 CFR
170.21,
the general information required by 10 CFR 50.33, and
the agreement limiting access to Classified Information
required by 10 CFR 50.37.
Thus, 10 CFR 2.101(a)(5) provides that applicable preliminary
safety analysis report information required by 10 CFR 50.34(a)(2)-
(a)(13) need not accompany the first part of the submittal. In order to
facilitate the review of its application, NWMI would like to submit its
application in two parts, as described above; however, based on the
current language of 10 CFR 51.20, it cannot do so unless granted an
exemption from certain provisions of 10 CFR 2.101(a)(5) by the
Commission.
The NRC staff previously addressed an exemption request from SHINE
Medical Technologies, Inc. (SHINE) to submit is construction permit
application in two parts. The NRC staff responded to a letter from
SHINE, dated July 10, 2012 (ADAMS Accession No. ML12214A434), that
asked whether production or utilization facility applicants could
submit a construction permit application in two parts even if an
environmental impact statement is not explicitly required for the
application by 10 CFR 51.20(b).
In a letter dated December 7, 2012 (ADAMS Accession No.
ML12319A192), the NRC staff responded:
SHINE's proposed action for licensing a medical isotope
production facility is not an action identified in 51.20(b);
therefore, 10 CFR 2.101(a)(5) is not applicable to SHINE's licensing
proposal. However, SHINE could apply for an exemption under 10 CFR
50.12 in order to submit its application for a construction permit
in two parts as described in 10 CFR 2.101(a)(5).
The NRC staff also explained that should an exemption to 10 CFR
2.101(a)(5) be sought, the request must set forth existing special
circumstances warranting the exemption, as well as provide the proposed
contents of each part of the construction permit application.
Similarly, NWMI has proposed to submit an application requesting
the issuance of a construction permit for a medical radioisotope
production facility--a licensing action not identified in 10 CFR
51.20(b). Therefore, its application for a construction permit cannot
be submitted in two parts under 10 CFR 2.101(a)(5) unless an exemption
is granted by the Commission.
2.0 Request/Action
Section 2.101(a)(5) of 10 CFR states, in part:
An applicant for a construction permit under part 50 of this
chapter . . . for a production or utilization facility which is
subject to Sec. 51.20(b) of this chapter, and is of the type
specified in Sec. 50.21(b)(2) or (b)(3) or Sec. 50.22 of this
chapter . . . may submit the information required of applicants by
part 50 . . . of this chapter in two parts.
By its letter dated August 9, 2013, NWMI requests an exemption from
the provision of 10 CFR 2.101(a)(5) that applications for a
construction permit under 10 CFR part 50 must be of the type requiring
an environmental impact statement or a supplement to an environmental
impact statement as described in 10 CFR 51.20(b). The exemption would
allow NWMI to submit a portion of its construction permit up to six
months prior to the submittal of the remainder of the application
regardless of whether an environmental impact statement or a
[[Page 63503]]
supplement to an environmental impact statement is prepared for its
construction permit application. Specifically, in accordance with the
provisions of 10 CFR 2.101(a)(5), NWMI proposes to submit the following
in part one of its construction permit application:
The description and safety assessment of the site required
by 10 CFR 50.34(a)(1),
the environmental report required by 10 CFR 50.30(f),
the filing fee required by 10 CFR 50.30(e) and 10 CFR
170.21,
the general information required by 10 CFR 50.33, and
the agreement limiting access to Classified Information
required by 10 CFR 50.37.
Part two of NWMI's construction permit application will contain the
remainder of the preliminary safety analysis report required by 10 CFR
50.34(a) and 2.101(a)(5). Northwest Medical Isotopes, LLC, has proposed
to ``design and construct a [radioisotope production facility] and
intends to produce Mo-99.'' In its request for an exemption from
certain requirements of 10 CFR 2.101(a)(5), NWMI states that the
``demand for medical isotopes is a significant national public health
and safety concern,'' and the ability to submit its construction permit
application in two parts would ``allow for an earlier determination as
to whether an [environmental impact statement] is required, allowing a
potential earlier completion of the environmental review and ultimate
issuance of the Construction Permit . . .''
3.0 Discussion
To docket NWMI's construction permit application in two parts under
10 CFR 2.101(a)(5), as proposed, an exemption to the regulations is
required. Pursuant to 10 CFR 50.12, the Commission may, upon
application by any interested person or upon its own initiative, grant
exemptions from the requirements of 10 CFR part 50 when (1) the
exemptions are authorized by law, will not present an undue risk to
public health or safety, and are consistent with the common defense and
security; and (2) when special circumstances are present. While the
action requested is not for an exemption to a 10 CFR part 50
regulation, it is appropriate to evaluate this exemption request using
the criteria of 10 CFR 50.12 because an application for a construction
permit for a radioisotope production facility cannot be accepted for
docketing in accordance with 10 CFR 2.101(a) unless it meets the
requirements of 10 CFR part 50.
Special Circumstances
The application of 10 CFR 2.101(a)(5) is limited to applications
for licensing actions that meet the criteria for environmental impact
statements as described in the provisions of 10 CFR 51.20(b) and to
facilities of the types specified in 10 CFR 50.21(b)(2) or (b)(3) or 10
CFR 50.22. Northwest Medical Isotopes, LLC, has proposed to submit an
application requesting the issuance of a construction permit for a
medical radioisotope production facility--a licensing action not
identified in 10 CFR 51.20(b). Consequently, its application for a
construction permit cannot be submitted in two parts under 10 CFR
2.101(a)(5) unless an exemption is granted by the Commission. The
Commission will not consider granting an exemption under 10 CFR 50.12
unless special circumstances are present. One of the special
circumstances listed in 10 CFR 50.12(a)(2) is ``(ii) [a]pplication of
the regulation in the particular circumstances would not serve the
underlying purpose of the rule or is not necessary to achieve the
underlying purpose of the rule.'' Therefore, should the Commission
determine that the underlying purpose of 10 CFR 2.101(a)(5) is
achieved, application of the regulation would not be necessary, and the
special circumstances would exist for granting of an exemption from
certain requirements of 10 CFR 2.101(a)(5).
The underlying purpose of the 10 CFR 2.101(a)(5) provision that
allows certain applicants to submit an application for a construction
permit in two parts is to enable the NRC review of significant portions
of the application, as they become available, without unnecessary
delay. The provision for two-part construction permit application
submittals was added as an amendment to the regulations of 10 CFR part
2, ``Agency Rules of Practice and Procedure,'' on April 24, 1974 (39 FR
14506). The intent of this final rule was to ``reduce the time required
to bring on line nuclear power plants which satisfy all environmental
and safety requirements . . . [and remove] unnecessary obstacles to the
construction of power plants needed to meet the nation's energy
needs.'' Recognizing the procedural nature of the amendment, the
Commission made the language of the final rule effective without the
customary 30-day notice. It is consistent with the procedural nature of
and rationale for the rule to allow NWMI to submit its construction
permit application in two parts to facilitate the licensing process of
this facility and NWMI's effort to respond to the nation's demand for a
domestic supply of Mo-99.
Furthermore, when the rule was originally written, there was a
``deep national concern over energy sources and supply.'' Similarly,
there currently exists a national concern over the sources and supply
of Mo-99 in the United States. Recognizing this concern, the U.S.
Department of Energy (DOE) and the National Nuclear Security
Administration (NNSA) are supporting four separate entities in the
development of low enriched uranium technologies to accelerate
commercial production of Mo-99 in the United States through the Global
Threat Reduction Initiative.\2\ By producing Mo-99 to meet emerging
domestic needs, NWMI's proposed medical radioisotope production
facility supports the efforts of DOE and NNSA and is in alignment with
the underlying purpose of 10 CFR 2.101(a)(5). Therefore, since the
underlying purpose of the rule is achieved, application of the
regulation is not necessary, and the special circumstances, required by
10 CFR 50.12(a)(2)(ii), exist for granting an exemption from certain
requirements of 10 CFR 2.101(a)(5).
---------------------------------------------------------------------------
\2\ To learn more about the Global Threat Reduction Initiative
and U.S. Department of Energy's support of domestic Mo-99
production, please visit https://nnsa.energy.gov/.
---------------------------------------------------------------------------
Additionally, in 2007, the rule language was modified to include
applicants seeking combined licenses under 10 CFR part 52, ``Licenses,
Certifications, and Approvals for Nuclear Power Plants'' (72 FR 49412).
The Commission determined that ``[t]here are no considerations unique
to combined licenses which would weigh against allowing a combined
license applicant to submit a two part application under paragraph
(a)(5) of Sec. 2.101.'' Similarly, the NRC staff concludes that given
the procedural nature of this rule, there are no unique considerations
for medical radioisotope production facilities that would weigh against
allowing an applicant such as NWMI to submit a two-part application
under 10 CFR 2.101(a)(5).
Authorized by Law
This exemption would allow NWMI to submit its application for a 10
CFR part 50 construction permit in two parts, as provided for in 10 CFR
2.101(a)(5). The exemption would not change the quality or content of
the environmental report or the preliminary safety analysis report. The
NRC staff has determined that special circumstances exist to
[[Page 63504]]
support the issuance of an exemption. Thus, the granting of the
proposed exemption is consistent with the Atomic Energy Act of 1954, as
amended, and the Commission's regulations. Therefore, the exemption is
authorized by law.
No Undue Risk to Public Health and Safety
As described above, the requested exemption is procedural in nature
and does not alter any substantive safety requirements regarding the
content of a construction permit application. Due to the procedural
nature of this request, no new accident precursors are created by
allowing an applicant to submit a construction permit application in
two parts; thus, the probability of postulated accidents is not
increased. Similarly, the consequences of postulated accidents are not
increased by an exemption that authorizes an application to be
submitted in two parts. Therefore, there is no undue risk \3\ to public
health and safety.
---------------------------------------------------------------------------
\3\ Risk is defined as the probability of an accident multiplied
by the consequences of an accident. More information on risk as it
is applies to NRC regulatory activities can be found in the
Commission White Paper on Risk-Informed and Performance Based
Regulation, SECY-98-144 (ADAMS Accession No. ML003753601).
---------------------------------------------------------------------------
Consistent With Common Defense and Security
As discussed above, the proposed exemption would allow NWMI to
submit its application for a 10 CFR part 50 construction permit
application in two parts as provided for in 10 CFR 2.101(a)(5). The
timing of submitting a construction permit application has no relation
to security issues. Therefore, the common defense and security is not
impacted by this exemption.
4.0 Conclusion
Accordingly, the Commission has determined that, pursuant to 10 CFR
50.12, the exemption is authorized by law, will not present an undue
risk to the public health and safety, and is consistent with the common
defense and security. Also, special circumstances are present.
Therefore, pursuant to 10 CFR 50.12, the Commission hereby grants NWMI
an exemption from the 10 CFR 2.101(a)(5) requirement that limits the
regulation's applicability to licensing and regulatory actions
requiring environmental impact statements, as described in the
provisions of 10 CFR 51.20(b). The exemption granted allows NWMI to
submit the construction permit application for its medical radioisotope
production facility in two parts, in accordance with the remainder of
the provisions of 10 CFR 2.101(a)(5).
Pursuant to 10 CFR 51.32, the Commission has determined that the
granting of this exemption will not have a significant effect on the
quality of the human environment as it is procedural in nature.
Furthermore, the Commission has determined that this exemption request
meets the criteria in 10 CFR 51.22(c)(25) for a licensing action that
is categorically excluded from the requirement to prepare an
environmental assessment because the granting of this exemption: (1)
Does not involve a significant increase in the probability or
consequences of an accident previously evaluated, does not create the
possibility of a new or different kind of accident from that previously
evaluated, and does not involve a significant reduction in the margin
of safety and, thus there is no significant hazards consideration; (2)
does not authorize the release of effluents, thus there is no
significant change in the types or significant increase in the amounts
of any effluents that may be released offsite; (3) neither authorizes
new radiological hazards nor increases existing radiological hazards,
thus there is no significant increase in individual or cumulative
public or occupational radiation exposure; (4) does not authorize
construction, thus there is no significant construction impact; (5)
does not authorize any placement of radiological components at a
facility or create any new accident precursors, thus there is no
significant increase in the potential for or consequences from
radiological accidents; and (6) allows the submission of a construction
permit application in two parts, and thus involves a scheduling
requirement in accordance with 10 CFR 51.22(c)(25)(vi)(G). This
exemption is effective upon issuance to NWMI.
Dated at Rockville, Maryland, this 7th day of October, 2013.
For the Nuclear Regulatory Commission.
Lawrence E. Kokajko,
Director, Division of Policy and Rulemaking, Office of Nuclear Reactor
Regulation.
[FR Doc. 2013-24882 Filed 10-23-13; 8:45 am]
BILLING CODE 7590-01-P